Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1979 Mar;39(3):247–258. doi: 10.1038/bjc.1979.48

Release of soluble "blocking" and "suppressor" factors from normal lymphocytes treated with RNA from spleens of tumour-bearing mice.

K J Pennline, S B Evans, J F Nawrocki, J C Rees, C S Johnson, D A Vallera, M C Dodd
PMCID: PMC2009868  PMID: 313804

Abstract

RNA extracted from the spleens of tumour-bearing (TLRNA) and tumour-immune (ILRNA) mice was shown to transfer to normal lymphocytes (NL) the ability to produce factors that blocked specific tumour-cell cytotoxicity and mediated specific antibody-dependent cell cytotoxicity (ADCC). Aliquots of normal C3H mouse lymphocytes were treated with TLRNA or ILRNA and cultured in vitro in the absence of tumour antigen. Supernatants were collected at 24h intervals and tested in a microcytotoxicity assay for blocking and ADCC activities. Factors that inhibited tumour destruction by specifically sensitized lymphocytes at the level of both the tumour cells and effector cells were demonstrable in culture supernatants of NL pretreated with TLRNA (50 or 100 microgram/4 X 10(6) cells) but not ILRNA. However, treatment of NL with either RNA resulted in the production factors that mediated tumour-specific ADCC. Cytotoxicity testing and absorption studies of the tumour cell and a control cell (LM) indicated that factors mediating ADCC and blocking at the target-cell level were specific for the tumour. Suppressor activity at the effector-cell level was not absorbed by tumour cells and represents a separate and distinct mechanism of immunosuppression. These data indicate that RNA faithfully transfers "suppressive" as well as "positive" types of immune responses that have been reported previously for lymphocytes obtained directly from tumour-bearing and tumour-immune animals.

Full text

PDF
247

Images in this article

251Fig. 1
on p.251
254Fig. 2
on p.254
254Fig. 3
on p.254
255Fig. 4
on p.255

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abramoff P., Brien N. B. Studies of the chicken immune response. II. Biologic activity of spleen "immunogenic RNA". J Immunol. 1968 Jun;100(6):1210–1214. [PubMed] [Google Scholar]
  2. Alexander P., Delorme E. J., Hamilton L. D., Hall J. G. Effect of nucleic acids from immune lymphocytes on rat sarcomata. Nature. 1967 Feb 11;213(5076):569–572. doi: 10.1038/213569a0. [DOI] [PubMed] [Google Scholar]
  3. Bell C., Dray S. Lymphoid cells converted by lymphoid RNA extracts in vitro and in vivo to synthesize allogeneic immunoglobulins. Ann N Y Acad Sci. 1973 May 31;207:200–224. doi: 10.1111/j.1749-6632.1973.tb47485.x. [DOI] [PubMed] [Google Scholar]
  4. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  5. Currie G. A., Basham C. Serum mediated inhibition of the immunological reactions of the patient to his own tumour: a possible role for circulating antigen. Br J Cancer. 1972 Dec;26(6):427–438. doi: 10.1038/bjc.1972.59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Deckers P. J., Wang B. S., Stuart P. A., Mannick J. A. The augmentation of tumor-specific immunity with immune RNA. Transplant Proc. 1975 Jun;7(2):259–263. [PubMed] [Google Scholar]
  7. Dodd M. C., Scheetz M. E., 2nd, Rossio J. L. Immunogenic RNA in the immunotherapy of cancer: the transfer of antitumor cytotoxic activity and tuberculin sensitivity to human lymphocytes using xenogeneic ribonucleic acid. Ann N Y Acad Sci. 1973 May 31;207:454–467. doi: 10.1111/j.1749-6632.1973.tb47508.x. [DOI] [PubMed] [Google Scholar]
  8. Greenup C. J., Vallera D. A., Pennline K. J., Kolodziej B. J., Dodd M. C. Anti-tumour cytotoxicity of poly(A)-containing messenger RNA isolated from tumour-specific immunogenic RNA. Br J Cancer. 1978 Jul;38(1):55–63. doi: 10.1038/bjc.1978.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Han T. 'Immune' RNA-mediated transfer of delayed skin reactivity in patients with Hodgkin's disease. Clin Exp Immunol. 1973 Jun;14(2):213–217. [PMC free article] [PubMed] [Google Scholar]
  10. Hellström I., Hellström K. E., Pierce G. E., Yang J. P. Cellular and humoral immunity to different types of human neoplasms. Nature. 1968 Dec 28;220(5174):1352–1354. doi: 10.1038/2201352a0. [DOI] [PubMed] [Google Scholar]
  11. Hellström I., Hellström K. E., Sjögren H. O., Warner G. A. Demonstration of cell-mediated immunity to human neoplasms of various histological types. Int J Cancer. 1971 Jan 15;7(1):1–16. doi: 10.1002/ijc.2910070102. [DOI] [PubMed] [Google Scholar]
  12. KUCHLER R. J., MERCHANT D. J. Propagation of strain L (Earle) cells in agitated fluid suspension cultures. Proc Soc Exp Biol Med. 1956 Aug-Sep;92(4):803–806. doi: 10.3181/00379727-92-22620. [DOI] [PubMed] [Google Scholar]
  13. Kern D. H., Chow N., Pilch Y. H. Kinetics of synthesis and immunologically active fraction of anti-tumor immune RNA. Cell Immunol. 1976 Jun 1;24(1):58–68. doi: 10.1016/0008-8749(76)90131-3. [DOI] [PubMed] [Google Scholar]
  14. Kern D. H., Drogemuller C. R., Pilch Y. H. Mediation of immune responses to tumor antigens in vitro by immune RNA. Ann N Y Acad Sci. 1976;276:278–302. doi: 10.1111/j.1749-6632.1976.tb41655.x. [DOI] [PubMed] [Google Scholar]
  15. Kern D. H., Pilch Y. H. Immune cytolysis of murine tumor cells mediated by xenogeneic "immune" RNA. Int J Cancer. 1974 May 15;13(5):679–688. doi: 10.1002/ijc.2910130512. [DOI] [PubMed] [Google Scholar]
  16. MANNICK J. A., EGDAHL R. H. TRANSFER OF HEIGHTENED IMMUNITY TO SKIN HOMOGRAFTS BY LYMPHOID RNA. J Clin Invest. 1964 Nov;43:2166–2177. doi: 10.1172/JCI105090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nelson K., Pollack S. B., Hellström K. E. Specific anti-tumor responses by cultured immune spleen cells. II. Culture supernatants induce specific anti-tumor cytotoxicity by non-immune lymphoid cells in vitro. Int J Cancer. 1975 Aug 15;16(2):292–300. doi: 10.1002/ijc.2910160212. [DOI] [PubMed] [Google Scholar]
  18. Pollack S., Heppner G., Brawn R. J., Nelson K. Specific killing of tumor cells in vitro in the presence of normal lymphoid cells and sera from hosts immune to the tumor antigens. Int J Cancer. 1972 Mar 15;9(2):316–323. doi: 10.1002/ijc.2910090209. [DOI] [PubMed] [Google Scholar]
  19. Pollack S. Specific "arming" of normal lymph-node cells by sera from tumor-bearing mice. Int J Cancer. 1973 Jan 15;11(1):138–142. doi: 10.1002/ijc.2910110116. [DOI] [PubMed] [Google Scholar]
  20. Pope B. L., Whitney R. B., Levy J. G., Kilburn D. G. Suppressor cells in the spleens of tumor-bearing mice: enrichment by centrifugation on hypaque-ficoll and characterization of the suppressor population. J Immunol. 1976 May;116(5):1342–1346. [PubMed] [Google Scholar]
  21. Ramming K. P., Pilch Y. H. Mediation of immunity to tumor isografts in mice by heterologous ribonucleic acid. Science. 1970 Apr 24;168(3930):492–493. doi: 10.1126/science.168.3930.492. [DOI] [PubMed] [Google Scholar]
  22. Rigby P. G. Prolongation of survival of tumour-bearing animals by transfer to "immune" RNA with DEAE-dextran. Nature. 1969 Mar 8;221(5184):968–969. doi: 10.1038/221968a0. [DOI] [PubMed] [Google Scholar]
  23. Schlager S. I., Paque R. E., Dray S. Complete and apparently specif local tumor regression using syngeneic or xenogeneic "tumor-immune" RNA extracts. Cancer Res. 1975 Aug;35(8):1907–1914. [PubMed] [Google Scholar]
  24. Sjögren H. O., Borum K. Tumor-specific immunity in the course of primary polyoma and Rous tumor development in intact and immunosuppressed rats. Cancer Res. 1971 Jun;31(6):890–900. [PubMed] [Google Scholar]
  25. Sjögren H. O., Hellström I., Bansal S. C., Hellström K. E. Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. Proc Natl Acad Sci U S A. 1971 Jun;68(6):1372–1375. doi: 10.1073/pnas.68.6.1372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. TING R. C., LAW L. W. THE ROLE OF THYMUS IN TRANSPLANTATION RESISTANCE INDUCED BY POLYOMA VIRUS. J Natl Cancer Inst. 1965 Apr;34:521–527. [PubMed] [Google Scholar]
  27. Takasugi M., Klein E. A microassay for cell-mediated immunity. Transplantation. 1970 Mar;9(3):219–227. doi: 10.1097/00007890-197003000-00005. [DOI] [PubMed] [Google Scholar]
  28. Takasugi M., Klein E. The role of blocking antibodies in immunological enhancement. Immunology. 1971 Oct;21(4):675–684. [PMC free article] [PubMed] [Google Scholar]
  29. Takei F., Levy J. G., Kilburn D. G. In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice. J Immunol. 1976 Feb;116(2):288–293. [PubMed] [Google Scholar]
  30. Thor D. E. Transfer of cell-mediated immunity by immune RNA assessed by migration-inhibition. Ann N Y Acad Sci. 1973 May 31;207:355–368. doi: 10.1111/j.1749-6632.1973.tb47498.x. [DOI] [PubMed] [Google Scholar]
  31. Ting C. C., Lavrin D. H., Takemoto K. K., Ting R. C., Herberman R. B. Expression of various tumor-specific antigens in polyoma virus-induced tumors. Cancer Res. 1972 Jan;32(1):1–6. [PubMed] [Google Scholar]
  32. Whitney R. B., Levy J. G. Mode of action of immunosuppressive substances in sera of tumor-bearing mice. J Natl Cancer Inst. 1975 Dec;55(6):1447–1452. doi: 10.1093/jnci/55.6.1447. [DOI] [PubMed] [Google Scholar]
  33. Wood W. C., Morton D. L. Microcytotoxicity test: detection in sarcoma patients of antibody cytotoxic to human sarcoma cells. Science. 1970 Dec 18;170(3964):1318–1320. doi: 10.1126/science.170.3964.1318. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES